publication . Article . 2020

Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates

Maisonnasse, Pauline; Guedj, Jérémie; Contreras, Vanessa; Behillil, Sylvie; Solas, Caroline; Marlin, Romain; Naninck, Thibaut; Pizzorno, Andres; Lemaitre, Julien; Gonçalves, Antonio; ...
Open Access English
  • Published: 01 Sep 2020
  • Publisher: HAL CCSD
  • Country: France
Abstract
International audience; Coronavirus disease 2019 (COVID-19) has rapidly become a global pandemic and no antiviral drug or vaccine is yet available for the treatment of this disease1-3. Several clinical studies are ongoing to evaluate the efficacy of repurposed drugs that have demonstrated antiviral efficacy in vitro. Among these candidates, hydroxychloroquine (HCQ) has been given to thousands of individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-the virus that causes COVID-19-worldwide but there is no definitive evidence that HCQ is effective for treating COVID-194-7. Here we evaluated the antiviral activity of HCQ both in vit...
Subjects
free text keywords: MESH: Animals, MESH: Azithromycin, MESH: Disease Models, Animal, MESH: Female, MESH: In Vitro Techniques, MESH: Humans, MESH: Hydroxychloroquine, MESH: Kinetics, MESH: Macaca fascicularis, MESH: Male, MESH: Pandemics, MESH: Pneumonia, Viral, MESH: Time Factors, MESH: Pre-Exposure Prophylaxis, MESH: Respiratory Mucosa, MESH: Treatment Failure, MESH: Betacoronavirus, MESH: Vero Cells, MESH: Viral Load, MESH: Chlorocebus aethiops, MESH: Coronavirus Infections, MESH: Cytokines, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, Multidisciplinary
Funded by
EC| Fight-nCoV
Project
Fight-nCoV
FIGHTING-OFF CORONAVIRUS (SARS-CoV-2) WITH BROAD-SPECTRUM ANTIVIRALS: ESTABLISHING ANIMAL VIRAL CHALLENGE MODEL
  • Funder: European Commission (EC)
  • Project Code: 101003555
  • Funding stream: H2020 | RIA
Validated by funder
,
EC| EVAg
Project
EVAg
European Virus Archive goes global
  • Funder: European Commission (EC)
  • Project Code: 653316
  • Funding stream: H2020 | RIA
Validated by funder
,
EC| TRANSVAC2
Project
TRANSVAC2
European Vaccine Research and Development Infrastructure
  • Funder: European Commission (EC)
  • Project Code: 730964
  • Funding stream: H2020 | RIA
,
ANR| IDMIT
Project
IDMIT
Infrastructure nationale pour la modélisation des maladies infectieuses humaines
  • Funder: French National Research Agency (ANR) (ANR)
  • Project Code: ANR-11-INBS-0008
Communities
Instruct-ERICInstruct-ERIC Projects: European Vaccine Research and Development Infrastructure
COVID-19covid-19 Projects: Fight-nCoV
33 references, page 1 of 3

1. He, X. et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat. Med. 26, 672-675 (2020).

2. Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497-506 (2020).

3. Chen, G. et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J. Clin. Invest. 130, 2620-2629 (2020).

4. Touret, F. & de Lamballerie, X. Of chloroquine and COVID-19. Antiviral Res. 177, 104762 (2020).

5. Touret, F. et al. In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication. Sci. Rep. 10, 13093 (2020).

6. Gautret, P. et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study. Travel Med. Infect. Dis. 34, 101663 (2020). [OpenAIRE]

7. Magagnoli, J. et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. Med 1, 1-14 (2020). [OpenAIRE]

8. Li, Q. et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N. Engl. J. Med. 382, 1199-1207 (2020).

9. Wang, M. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 30, 269-271 (2020).

10. Liu, J. et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 6, 16 (2020).

11. Ponticelli, C. & Moroni, G. Hydroxychloroquine in systemic lupus erythematosus (SLE). Expert Opin. Drug Saf. 16, 411-419 (2017).

12. Savarino, A., Di Trani, L., Donatelli, I., Cauda, R. & Cassone, A. New insights into the antiviral effects of chloroquine. Lancet Infect. Dis. 6, 67-69 (2006).

13. Rainsford, K. D., Parke, A. L., Clifford-Rashotte, M. & Kean, W. F. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology 23, 231-269 (2015).

14. Schrezenmeier, E. & Dörner, T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat. Rev. Rheumatol. 16, 155-166 (2020).

15. Monzavi, S. M. et al. Efficacy analysis of hydroxychloroquine therapy in systemic lupus erythematosus: a study on disease activity and immunological biomarkers. Inflammopharmacology 26, 1175-1182 (2018).

33 references, page 1 of 3
Any information missing or wrong?Report an Issue